Appendiceal Cancer Clinical Trial
Official title:
Surgical Outcome and Predictors of Overall Survival of Stage I-III Appendiceal Adenocarcinoma; a National Cancer Database Analysis
NCT number | NCT05452382 |
Other study ID # | NCDBAppendix |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2005 |
Est. completion date | July 6, 2022 |
Verified date | July 2022 |
Source | Mansoura University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
A few studies investigated the predictors of overall survival in appendiceal adenocarcinoma. A SEER database analysis of 1404 patients with appendiceal adenocarcinoma found that older age, T4 tumors, N1-2 stage, poorly differentiated carcinoma, and distant metastasis were significantly predictive of poorer survival. Another small single-center study including 49 appendiceal cancer patients reported female gender and low-grade adenocarcinoma to be associated with increased overall survival. However, these previous analyses did not take into account some important prognosticators of survival such as patients' comorbidities and functional status, pathologic parameters such as lymphovascular invasion, and adjuvant systemic treatment. Therefore, we used the National Cancer Database (NCDB) to conduct a comprehensive analysis of the predictors of overall survival after surgical treatment of stage I-III appendiceal adenocarcinoma.
Status | Completed |
Enrollment | 2607 |
Est. completion date | July 6, 2022 |
Est. primary completion date | December 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - patients with non-metastatic appendiceal adenocarcinoma who underwent surgical resection Exclusion Criteria: - Patients with other pathologic types of appendiceal cancer - Patients with clinical stage IV or unknown stage - Patients who did not undergo surgery, underwent local excision, or had unknown/non-specified surgery |
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic Flroida | Weston | Florida |
Lead Sponsor | Collaborator |
---|---|
Mansoura University | Cleveland Clinic Florida |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival | Percent of patients who were alive at five years of follow-up | 60 months | |
Secondary | Positive resection margins | the rate of surgical margins infiltrated by malignancy | Immediate postoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT06101277 -
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
|
N/A | |
Recruiting |
NCT04847063 -
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
|
Phase 1 | |
Recruiting |
NCT05185947 -
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
|
Phase 2 | |
Completed |
NCT02040142 -
Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C
|
Phase 2 | |
Recruiting |
NCT05734430 -
Genetics of Appendix Cancer Study
|
||
Completed |
NCT03604653 -
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
|
||
Terminated |
NCT04158349 -
Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05364788 -
Molecular Characterisation of Appendiceal Cancer
|
||
Recruiting |
NCT05194995 -
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
|
Phase 1/Phase 2 |